Allergy medication and hair loss is a concern raised by many people managing long-term allergic conditions. While most standard antihistamines — such as cetirizine, loratadine, and fexofenadine — are not commonly associated with hair shedding, certain systemic allergy treatments may occasionally contribute to a temporary condition called telogen effluvium. The relationship is rarely straightforward, as the underlying allergic condition, nutritional factors, and stress can all independently affect hair health. This article explores which allergy medications carry a documented risk, who may be most vulnerable, and what steps to take if you notice unusual hair changes.

Can Allergy Medication Cause Hair Loss?

Most allergy medications are not a recognised cause of hair loss, but some systemic treatments may trigger telogen effluvium — a temporary, diffuse shedding that typically resolves within 6–9 months once the trigger is addressed.

Not sure if this is normal? Chat with one of our pharmacists →

Hair loss, known medically as alopecia, can arise from a wide range of causes — including hormonal changes, nutritional deficiencies, autoimmune conditions, and certain medications. When it comes to allergy medication and hair loss, the relationship is not straightforward, and for most people taking standard antihistamines or allergy treatments, hair loss is not a recognised or common side effect.

That said, a subset of medications used to manage allergic conditions — including some systemic treatments — have been associated with a type of hair loss called telogen effluvium (TE). This occurs when a physiological or pharmacological stressor pushes a larger-than-normal proportion of hair follicles into the resting (telogen) phase prematurely, leading to diffuse shedding. Typically, TE begins around 2–3 months after the trigger and, once the trigger is identified and addressed, hair usually recovers within 6–9 months. The evidence linking standard antihistamines specifically to TE is limited to rare case reports and spontaneous adverse event reports; no robust causal relationship has been established.

It is important to note that the underlying allergic condition itself — particularly if it involves significant immune dysregulation or chronic stress — may contribute to hair changes independently of any medication. Alopecia areata, for example, is an autoimmune condition that can co-exist with atopic conditions such as eczema and asthma, and can directly affect the scalp and hair follicles. Therefore, attributing hair loss solely to allergy medication requires careful clinical assessment. If you notice unusual hair shedding after starting a new allergy treatment, discuss this with a GP or pharmacist rather than stopping the medication abruptly.

If you suspect a medication is causing hair loss, you can report this to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Which Antihistamines and Allergy Treatments Are Linked to Hair Loss

Standard antihistamines are rarely linked to hair loss; systemic corticosteroids, immunosuppressants such as methotrexate, and the monoclonal antibody dupilumab carry a more credible, though still uncommon, association.

Most first- and second-generation antihistamines — such as cetirizine, loratadine, fexofenadine, and chlorphenamine — are generally well tolerated and alopecia is not commonly reported with their use. Where alopecia does appear in some antihistamine Summaries of Product Characteristics (SmPCs), it is listed at very rare or unknown frequency. Patients and clinicians should check the relevant SmPC (available via the MHRA/electronic Medicines Compendium) for the specific product being used. There is no established causal regulatory link between standard antihistamines and clinically significant hair loss.

The allergy treatments more credibly associated with hair changes include:

• Systemic corticosteroids (e.g., prednisolone): Prolonged use can disrupt the hair growth cycle and has been associated with telogen effluvium in some individuals, though hirsutism (increased body hair) is a more commonly recognised effect of long-term systemic steroid use. Hair effects are uncommon and should be assessed in the context of the overall risk–benefit of treatment.

• Immunosuppressants (e.g., azathioprine, methotrexate): Used in severe allergic or atopic conditions, these agents carry a recognised but uncommon risk of hair thinning or loss. Ciclosporin, by contrast, more commonly causes hypertrichosis (excess hair growth) and is sometimes used therapeutically in alopecia areata — it is not typically associated with hair loss.

• Monoclonal antibodies (e.g., dupilumab, used for severe atopic eczema): Cases of alopecia and alopecia areata have been reported post-marketing. The causal relationship has not been firmly established; patients and prescribers should consult the current dupilumab SmPC and EMA EPAR for the most up-to-date adverse reaction information.

• Nasal corticosteroid sprays (e.g., fluticasone propionate, mometasone, budesonide): When used as directed, systemic absorption is minimal, and hair loss is not a recognised side effect at standard doses.

Understanding which specific medication within an allergy treatment regimen may be responsible is key to appropriate management, and this distinction should be made with professional guidance.

How Common Is Medication-Related Hair Loss and Who Is at Risk

Medication-induced hair loss from allergy treatments is uncommon; those with a personal history of alopecia, iron deficiency, thyroid dysfunction, or polypharmacy are at greatest risk.

Medication-induced hair loss is generally considered uncommon, and when it does occur, it is most often temporary and reversible once the causative agent is identified and addressed. In the context of allergy treatments specifically, the incidence of hair loss is low, and robust epidemiological data are limited. Most evidence comes from case reports, pharmacovigilance databases, and post-marketing surveillance rather than large randomised controlled trials.

Certain individuals may be at greater risk of experiencing hair changes when taking allergy medications:

• Those with a personal or family history of alopecia areata or androgenetic alopecia, as their hair follicles may be more susceptible to pharmacological triggers.

• Individuals on multiple medications, where polypharmacy increases the cumulative risk of drug-induced hair loss.

• People with iron deficiency or thyroid dysfunction, which are among the most common reversible causes of hair shedding in the UK and should be excluded early in any assessment.

• Those undergoing prolonged courses of systemic immunosuppressants for severe allergic disease.

Telogen effluvium typically begins 2–3 months after a trigger and usually improves within 6–9 months once the underlying cause is addressed, which can be reassuring for those affected.

It is also worth considering that stress — both physical and psychological — associated with managing a chronic allergic condition can itself trigger telogen effluvium, making it difficult to isolate the medication as the sole cause. A thorough clinical history is essential to disentangle these contributing factors.

Note: If you are taking biotin (vitamin B7) supplements, inform your clinician before having blood tests. The MHRA has issued guidance that biotin can interfere with a range of laboratory assays and may produce falsely abnormal results.

When to Speak to a GP or Pharmacist About Hair Changes

See a GP if hair loss is sudden, patchy, accompanied by scalp changes, or affecting your wellbeing; a pharmacist can review medications and signpost to appropriate care without you needing to stop treatment independently.

Not all hair shedding requires urgent medical attention — it is normal to lose between 50 and 100 hairs per day. However, if you notice a significant increase in hair loss, patchy bald areas, or thinning that coincides with starting or changing an allergy medication, it is sensible to seek professional advice.

You should contact your GP if:

• Hair loss is sudden, patchy, or accompanied by scalp inflammation, itching, or scarring.

• You are losing hair in clumps or noticing significant thinning.

• Hair loss is affecting your psychological wellbeing or quality of life.

• You have other symptoms such as fatigue, weight changes, or skin changes that may suggest an underlying systemic cause (e.g., thyroid dysfunction or iron deficiency anaemia).

A pharmacist can help by:

• Reviewing your current medications for known interactions or documented side effects.

• Discussing your concerns and, where appropriate, liaising with your prescriber about possible alternatives — any change to a prescribed medicine should be agreed with the prescribing clinician rather than made independently.

• Signposting you to appropriate NHS resources or NICE-aligned guidance.

Your GP may arrange blood tests to exclude common causes of hair loss. In UK primary care, core investigations typically include thyroid function (TSH), a full blood count (FBC), and serum ferritin. Additional tests — such as vitamin D, vitamin B12, or coeliac serology — may be considered if clinically indicated. Routine testing for zinc or biotin deficiency is not standard practice in the UK unless there is a specific clinical reason.

Your GP may refer you to a dermatologist if the cause remains unclear, if hair loss is rapidly progressive, or if features suggest scarring alopecia, which requires prompt specialist assessment. Do not stop prescribed allergy medication without first consulting your GP, as this could lead to a worsening of your allergic condition.

Managing Hair Loss While Continuing Allergy Treatment

If allergy treatment remains clinically necessary, focus on correcting nutritional deficiencies, gentle hair care, and scalp health; telogen effluvium typically improves within 6–9 months once the underlying trigger is managed.

If a medication is identified as a likely contributor to hair loss but remains clinically necessary, the focus shifts to minimising impact and supporting hair health alongside ongoing treatment. In many cases, hair loss associated with allergy medications is temporary. Telogen effluvium typically begins to improve within a few months of the trigger being resolved, with most people seeing meaningful recovery within 6–9 months.

Practical steps that may help include:

• Correcting nutritional deficiencies: Iron deficiency is one of the most common and treatable contributors to hair shedding in the UK. If blood tests confirm a deficiency, your GP will advise on appropriate supplementation. A balanced diet providing adequate protein supports healthy hair growth. Zinc and biotin supplements are not routinely recommended unless a deficiency has been confirmed, and if you do take biotin, inform your clinician before blood tests, as it can interfere with laboratory assays (MHRA Drug Safety Update).

• Gentle hair care: Avoiding excessive heat styling, tight hairstyles, and harsh chemical treatments can reduce mechanical stress on already vulnerable hair follicles.

• Scalp health: Keeping the scalp clean and well-moisturised is particularly relevant for those with atopic conditions, where scalp inflammation may compound other effects on hair.

• Psychological support: Hair loss can significantly affect self-esteem and mental health. NHS Talking Therapies or referral to a counsellor may be appropriate for those experiencing distress.

In some cases, a dermatologist may consider topical minoxidil. It is licensed for androgenetic alopecia; its use in telogen effluvium is off-label with limited evidence, and a specialist assessment is advisable before starting it. NICE does not currently provide specific guidance on medication-induced alopecia, but management is generally guided by identifying and addressing the underlying cause while supporting the patient holistically. Open communication with your healthcare team about the impact of hair loss on your quality of life is encouraged.

Alternative Allergy Medications With a Lower Risk of Hair Loss

Second-generation antihistamines (fexofenadine, loratadine) and intranasal corticosteroids carry a very low documented risk of hair loss and remain first-line options in UK primary care for allergic rhinitis and urticaria.

For individuals concerned about allergy medication and hair loss, it may be reassuring to know that several effective allergy treatments carry a very low documented risk of affecting hair. Second-generation antihistamines — including fexofenadine and loratadine — are generally well tolerated; alopecia is not commonly reported with their use, and where it appears in product information it is listed at very rare or unknown frequency. These remain first-line options in UK primary care for the management of allergic rhinitis and urticaria, in line with NICE CKS guidance and NHS recommendations.

Have questions about your medication? Our pharmacists are here to help →

For those requiring treatment for more complex or severe allergic conditions, the following considerations may be relevant:

• Intranasal corticosteroids (e.g., fluticasone propionate, budesonide, mometasone): These are highly effective for allergic rhinitis with minimal systemic absorption at recommended doses, making hair loss an unlikely concern.

• Sodium cromoglicate (available as eye drops or nasal spray): A mast cell stabiliser with a well-established safety profile and no known association with hair loss.

• Allergen immunotherapy (desensitisation): For eligible patients, NICE has appraised specific sublingual immunotherapy (SLIT) tablets for grass pollen and house dust mite allergies. This specialist-led approach addresses the underlying allergic response and may reduce the need for long-term pharmacological treatment. It carries a small risk of allergic reactions, including anaphylaxis, and must be initiated and supervised by a specialist.

• Leukotriene receptor antagonists (e.g., montelukast): Not commonly associated with hair loss. However, the MHRA has issued a Drug Safety Update on the risk of neuropsychiatric adverse effects (including sleep disturbances, anxiety, and depression) with montelukast; this should be discussed with a prescriber before starting treatment.

Any switch in allergy medication should be made in consultation with a GP or allergy specialist to ensure that the change is clinically appropriate and that allergy control is maintained. Self-substituting medications without professional advice is not recommended.

If you believe any allergy medication is causing hair loss or another side effect, please report it to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Frequently Asked Questions